In this edition
- AMS Webinar: Vasomotor symptom (VMS) management with non-hormonal options
- Menopause Down Under, Sydney | Saturday 6 April 2024
- IMS World Congress on Menopause in Melbourne 2024
- ASPOG 2024 Breaking the Boundaries, Bridging gaps
Health Professionals - join AMS for Members-only content
- Menopausal Hormone Therapy (MHT) discontinuation and shortages February 2024
- Vasomotor symptoms and sleep disturbance in menopause: a systematic review focused on ethnicity differences
- Hormones and Stroke: An update on treatment and risk
- Our Menopause World
- European Menopause and Andropause Society (EMAS) Newsletter
AMS Webinar: Vasomotor symptom (VMS) management with non-hormonal options
Join us online at 7.00pm on Thursday 21 March 2024 for the AMS Webinar: Vasomotor symptom (VMS) management with non-hormonal options. This webinar is targeted at GPs, specialists and allied health workers who are seeking a comprehensive update on non-hormonal therapies for VMS. Although menopausal hormone therapy (MHT) is the most effective option for management of VMS and genitourinary symptoms, some women are unable to use MHT, for personal or health reasons.
Dr Sonia Davison, Endocrinologist and AMS Past-President will take us through evidence-based non-hormonal options for vasomotor symptoms, including a new therapy using a neurokinin 3 (NK3) receptor antagonist. AMS President Dr Sylvia Rosevear will chair the meeting and there will be plenty of time for questions.
AMS Webinar: Vasomotor symptom management with non-hormonal options | 21 Mar 2024
*Registration fees:
AMS members: Free
General admission: $20
Registration: https://www.trybooking.com/CPFMS
*Please note that only AMS members or health professionals registered with AHPRA or MCNZ are able to register and attend. A Zoom link to the webinar will be emailed to attendees 24 hours before the event.
The event is being recorded and the recording will be made available to all registered delegates after the event.
Menopause Down Under, Sydney | Saturday 6 April 2024
AMS is excited to announce that we will be hosting Menopause Down Under at Rydges World Square, Sydney on Saturday 6 April 2024.
This whole day event will focus on midlife women's health issues down under.
Join us for an up-to-date discussion on the fundamentals of menopause medicine, management of bleeding whilst on menopausal hormonal therapy, pelvic floor dysfunction and incontinence, and management of genitourinary syndrome of the menopause.
There will be a panel discussion on managing complex cases and we encourage you to send in your case study by 22 March 2024 to ams@menopause.org.au for discussion by the panel.
This is a great opportunity to hear from some of Australia's experts in the field of midlife women's health and to network with colleagues.
This face-to-face event will also be live-streamed for health professionals who cannot make it to Sydney.
Please note that online attendees will not be able to ask questions of the presenters. However, we still encourage online delegates to send us your complex cases for discussion by our expert panel by 22 March 2024 to ams@menopause.org.au
Registration
| |
AMS members
|
General Admission
|
|
Face-to-Face
|
$49
|
$149
|
|
Online
|
$20
|
$59
|
Booking
Menopause Down Under
Program
See Program and information on Speakers online here
IMS World Congress on Menopause in Melbourne 2024
Registrations are now open for the IMS World Congress in Melbourne this October. AMS members have access to the same discounted IMS member rate for the IMS World Congress on Menopause in Melbourne, 19-22 October 2024.
Early Bird closes on 26 March 2024.
Registration for Australian and New Zealand trainees is FREE until 23 September 2024.
We look forward to welcoming you to the IMS World Congress on Menopause.
ASPOG 2024 Breaking the Boundaries, Bridging gaps
We invite you to come along to ASPOG 2024 to be held in Melbourne. The theme of the meeting is ’Breaking the Boundaries, Bridging gaps’, and we have a well informed and fascinating program of talks and discussions on diverse clinical and psychosocial aspects of women's health, delivered by experts from a variety of health disciplines. Faculty for the two days includes Prof Martha Hickey, Prof Cassandra Szoeke, Dr Sara Whitburn, Prof Catherine Chamberlain, Susan McClean and Dr Hazel Keedle. This year a ‘Breakfast Panel’, Sat 4th, has been included: adiscussion around birth trauma with obstetrician and RANZCOG Council Member Dr Nisha Khot, midwife Dr Rakime Elmir, and perinatal psychiatrist Jo Power. Light Continental Breakfast will be provided, coffee, juice, fruit and pastry.
Call for papers is open, details can be found here
Health Professionals - join AMS for Members-only content
Menopausal Hormone Therapy (MHT) discontinuation and shortages February 2024
Australia
Please note that Femoston-Conti 1/5 has been delisted from the PBS and is only available on private script from 1 December 2024. Patients who have been prescribed Femoston-Conti 1/5 before 1 December 2024 will be able to have it dispensed at the PBS listed price until 1 March 2024. We understand that the delisting is a commercial decision made by the sponsor. While private scripts prices fluctuate between pharmacies, it is currently being sold at a large pharmacy chain for $11.99.
Patch Shortages
There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products for supply under Section 19A. Patch availability including alternative supplies are provided in the tables below:...
IMS Live February 26, 2024: Vasomotor symptoms and sleep disturbance in menopause: a systematic review focused on ethnicity differences
Several studies have reported racial/ethnicity differences in the prevalence of vasomotor symptoms (VMS), sleep disturbance and VMS treatment for menopause. In order to assess the reproducibility of these differences, recently Kingsberg et al. [1] systematically reviewed observational studies which were published between 2000 and 2021 and reported on the prevalence/incidence of VMS, sleep disturbance or treatment use in menopausal women stratified by race/ethnicity. The authors screened 3,799 records extracted from PubMed and Embase and included 27 papers (19 studies). Incidence data was not found. Prevalence data varied widely, but some common patterns emerged. In all five studies comparing VMS between Black women and White, Hispanic and/or East Asian women, the prevalence was highest in Black women and lowest in East Asian women. Overall, the prevalence of sleep disturbance was compared among Black, White and East Asian women in two study populations, and was highest in White women in both papers. Sleep disturbance was more common than VMS in East Asian women. In all four studies comparing hormone therapy use between White women and Black and/or East Asian women, treatment use was more common in White women...
Hormones and Stroke: An update on treatment and risk - IMS webinar online now
Moderator: Prof Antonio Cano
Speakers: Dr Matthew Nudy: ‘Hormonal effects on the risk of stroke’
Prof Dominique Cadilhac: ‘New treatments in stroke prevention and management’
Our Menopause World See a copy of the latest from IMS.
European Menopause and Andropause Society (EMAS) Newsletter AMS is an affiliate of EMAS. See latest copy.
